MediMedia Managed Markets


Peer-Reviewed Articles from Managed Care

Research Articles from Managed Care

Paul Abourjaily, PharmD ; William A. Gouveia, MS ; Harry P. Selker, MD, MSPH ; Deborah R. Zucker, MD, PhD
Substantial nondrug costs result from switching prescribed medications in response to changes in insurance coverage, and many nonreimbursed costs shift to providers and patients.
Janice Frates, PhD ; Ellen Severoni, RN
As CDHPs increasingly penetrate the commercial market , their greatest contribution might lie in funding health services for retirees and in reducing the number of uninsured people by offering affordable insurance.
Mary Ann Clark, MHA
This study is the first to estimate costs and medical resource use associated with restenosis involving bare metal stents in managed care percutaneous coronary intervention patients.
Mark Zitter, MBA
This article evaluates recent trends and challenges in health system management of exceedingly rare genetic diseases, from the perspective of the manufacturer, managed care organization, physician, and actuary.
David G. Lombardi, MD ; Niki B. Istwan, RN ; Debbie J. Rhea, MPH ; John M. O'Brien, MD ; John R. Barton, MD
In this study, outpatient management was effective in controlling nausea and vomiting during pregnancy and was associated with a reduced need for hospital or emergency room treatment as well as reduced costs.
Thomas Morrow, MD
Along with traditional systemic therapies, the American Academy of Dermatology recommends four biologic agents as first-line treatment for psoriasis patients who are candidates for systemic therapy.
Michael D. Cabana, MD, MPH ; Randall Brown, MD, MPH ; Noreen M. Clark, PhD ; Diane F. White, RRT ; Juanita Lyons, PhD ; Sylvia Wanner Lang, PhD ; Susan L. Bratton, MD, MPH
Although interactive educational seminars that target physicians require a large investment of resources, they can be cost-effective if medical care is improved as a result.
Udaya M. Kabadi, MD
Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise.
David W. Dodick, MD ; Robert J. Lipsy, PharmD
In response to the expense of new migraine therapies, treatment practices aimed at controlling direct costs are now the norm.
Gailen D. Marshall Jr., MD, PhD
Omalizumab, a novel therapy that targets specific steps in the inflammatory cascade of asthma, may benefit the hard-to-treat patient.